UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported): December 8, 2017
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
NEVADA
|
001-37761
|
20-5093315
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
343 Allerton Ave.
South San Francisco, California 94090
|
|
(Address of principal executive offices)
|
(650)
577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR 240.12b-2) ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act ☐
On December
8, 2017, VistaGen Therapeutics, Inc. (the
“Company”)
announced that the U.S. Patent and Trademark Office
(“USPTO”) issued new U.S. Patent No.
9,834,754 related to methods for producing, from human pluripotent stem
cells (hPSCs), hematopoietic precursor stem cells with the
potential to impact both direct and supportive therapy for
autoimmune disorders and cancer, with CAR-T cell applications and
foundational technology which may provide approaches for producing
bone marrow stem cells for bone marrow transfusions. VistaGen holds
an exclusive license to this newly issued U.S. patent from the
University Health Network in Toronto. A copy of the press release
is attached to this Current Report on Form 8-K as Exhibit 99.1, and
is incorporated herein by reference.
Item 9.01
Financial Statements and
Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
|
Date:
December 8, 2017
|
By:
|
/s/ Shawn K. Singh
|
|
|
|
Shawn K.
Singh
Chief Executive
Officer
|
EXHIBIT INDEX
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press release
issued by VistaGen Therapeutics Inc., dated December 8,
2017.
|